PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy
NetScientific notes that portfolio company, PDS Biotechnology Corp., has announced positive preliminary data showing that its lead cancer immunotherapy treatment, PDS0101, has generated strong T-cell responses in pre-cervical cancer.
Currently, pre-cervical cancer is treated by surgical removal of lesions however; PDS0101 could offer an effective non-surgical alternative. Results show that it primes and activates the body’s defense mechanisms (T-cells) to recognize, target, and kill precancerous and cancerous cells that display HPV viral proteins, which are responsible for over 99% of cervical cancers. The patient population tested were those most likely to develop invasive cancer as they had little to no pre-treatment immune responses to HPV-16.
The results are the first demonstration of PDS Biotechnology’s proprietary synthetic immunotherapy technology, Versamune’s®, application in human cancer. They also mirror preclinical data which showed strong T-cell responses and aggressive tumor regression with low doses of the product. The results mark an important step towards the development of next generation therapies to treat early and late stage cancers and suggest that Versamune® could be used by other immuno-oncology platform technologies.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Hitchhiking his way to better drug delivery - Harnessesing blood cells to help nanoparticles cross biological barriers

Dr. Christie Hunter wins HUPO 2013 Science and Technology Award - AB SCIEX proteomics scientist is recognized for her role in advancing targeted proteomics
Probiodrug Further Expands Scientific Advisory Board by Appointing Prof Dr Dr hc Christian Haass
Anti-tumor protein isolated from ink of a sea slug destroys various kinds of cancers
List_of_papaya_diseases

New 'NanoZymes' use light to kill bacteria - Artificial enzymes could be used in hospitals and toilets
Generex Publishes Results From Pre-Clinical Studies On Immunotherapeutic Vaccine for HPV-Induced Cervical Cancer
